IL82351A - Compositions for the treatment of viral and cancerous skin lesions - Google Patents

Compositions for the treatment of viral and cancerous skin lesions

Info

Publication number
IL82351A
IL82351A IL82351A IL8235187A IL82351A IL 82351 A IL82351 A IL 82351A IL 82351 A IL82351 A IL 82351A IL 8235187 A IL8235187 A IL 8235187A IL 82351 A IL82351 A IL 82351A
Authority
IL
Israel
Prior art keywords
viral
compositions
treatment
skin
cancerous skin
Prior art date
Application number
IL82351A
Other languages
English (en)
Original Assignee
Exovir Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exovir Inc filed Critical Exovir Inc
Priority to IL82351A priority Critical patent/IL82351A/xx
Publication of IL82351A publication Critical patent/IL82351A/xx

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60D—VEHICLE CONNECTIONS
    • B60D1/00—Traction couplings; Hitches; Draw-gear; Towing devices
    • B60D1/58—Auxiliary devices
    • B60D1/66—Props
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2073—IL-11
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transportation (AREA)
  • Mechanical Engineering (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL82351A 1986-02-18 1987-04-28 Compositions for the treatment of viral and cancerous skin lesions IL82351A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL82351A IL82351A (en) 1986-02-18 1987-04-28 Compositions for the treatment of viral and cancerous skin lesions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/830,662 US4822605A (en) 1986-02-18 1986-02-18 Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like
IL82351A IL82351A (en) 1986-02-18 1987-04-28 Compositions for the treatment of viral and cancerous skin lesions

Publications (1)

Publication Number Publication Date
IL82351A true IL82351A (en) 1990-12-23

Family

ID=25257431

Family Applications (1)

Application Number Title Priority Date Filing Date
IL82351A IL82351A (en) 1986-02-18 1987-04-28 Compositions for the treatment of viral and cancerous skin lesions

Country Status (10)

Country Link
US (1) US4822605A (de)
EP (1) EP0233629B1 (de)
JP (1) JPS62240627A (de)
AT (1) ATE68702T1 (de)
AU (1) AU598232B2 (de)
CA (1) CA1297006C (de)
DE (1) DE3773953D1 (de)
DK (1) DK82287A (de)
IL (1) IL82351A (de)
ZA (1) ZA87702B (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ219027A (en) * 1986-01-24 1989-09-27 Genentech Inc Antiviral composition containing interferon tumour necrosis factor and/or lymphotoxin
US4879111A (en) * 1986-04-17 1989-11-07 Cetus Corporation Treatment of infections with lymphokines
US5028422A (en) * 1986-05-27 1991-07-02 Schering Corporation Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
IE62318B1 (en) * 1986-05-27 1995-01-25 Schering Corp Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
IL80005A (en) * 1986-09-10 1992-11-15 Yeda Res & Dev Compositions for modulating the effect of tnf and il-1
US4929442A (en) * 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
US4980160A (en) * 1986-10-16 1990-12-25 Biogen, Inc. Combinations of tumor necrosis factors and anti-inflammatory agents and methods for treating malignant and non-malignant diseases
CA1292686C (en) * 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
US4963354A (en) * 1987-01-21 1990-10-16 Genentech, Inc. Use of tumor necrosis factor (TNF) as an adjuvant
DE3731255A1 (de) * 1987-09-17 1989-04-06 Boehringer Ingelheim Int Stabilisierung von therapeutisch wirksamen proteinen in pharmazeutischen zubereitungen
US5266310A (en) * 1987-09-17 1993-11-30 Boehringer Ingelheim International Gmbh Stabilization of therapeutically active proteins in pharmaceutical preparations
US6060459A (en) * 1987-10-28 2000-05-09 Pro-Neuron, Inc. Enhancing blood cell count with oxypurine nucleosides
US6241982B1 (en) * 1988-03-21 2001-06-05 Chiron Corporation Method for treating brain cancer with a conditionally lethal gene
US5342613A (en) * 1988-12-27 1994-08-30 Health Research Inc. Pharmaceutical compositions and use thereof in the treatment of psoriasis
ES2034790T3 (es) * 1989-04-11 1993-04-01 Boehringer Ingelheim International Gmbh Empleo de al menos una citroquina para la preparacion de un medicamento para el tratamiento sistematico de lesiones preneoplasticas.
US5028421A (en) * 1989-05-25 1991-07-02 Embrex, Inc. Method of treating birds
JP3203599B2 (ja) * 1989-10-24 2001-08-27 カイロン コーポレイション 感染性タンパク質デリバリーシステム
US5795964A (en) * 1990-06-27 1998-08-18 Biogen, Inc. Lymphotoxin-beta and lymphotoxin-beta complexes
DK0536299T3 (da) * 1990-06-27 2001-07-09 Univ California Overfladekompleksbundet lymfotolksin
US7030080B2 (en) * 1990-06-27 2006-04-18 Biogen, Inc. Lymphotoxin-β, lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
US5082472A (en) * 1990-11-05 1992-01-21 Mallouk Robert S Composite membrane for facilitated transport processes
JP3552240B2 (ja) * 1993-02-23 2004-08-11 第一製薬株式会社 高濃度ｔｃｆ製剤
IL112649A (en) * 1994-02-22 1999-12-22 Curtis Helene Ind Inc Topically effective compositions for application to the skin or hair
US5547661A (en) * 1994-02-22 1996-08-20 Helene Curtis, Inc. Antiperspirant deodorant compositions
US5888814A (en) * 1994-06-06 1999-03-30 Chiron Corporation Recombinant host cells encoding TNF proteins
US5599614A (en) * 1995-03-15 1997-02-04 W. L. Gore & Associates, Inc. Integral composite membrane
US5547551A (en) * 1995-03-15 1996-08-20 W. L. Gore & Associates, Inc. Ultra-thin integral composite membrane
US6254978B1 (en) 1994-11-14 2001-07-03 W. L. Gore & Associates, Inc. Ultra-thin integral composite membrane
USRE37307E1 (en) 1994-11-14 2001-08-07 W. L. Gore & Associates, Inc. Ultra-thin integral composite membrane
USRE37701E1 (en) * 1994-11-14 2002-05-14 W. L. Gore & Associates, Inc. Integral composite membrane
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
AU722042B2 (en) * 1995-11-30 2000-07-20 Board Of Regents, The University Of Texas System Methods and compositions for the diagnosis and treatment of cancer
US20030190307A1 (en) * 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
JP4006058B2 (ja) * 1997-03-11 2007-11-14 第一三共株式会社 多臓器不全予防及び／又は治療剤
CA2253629A1 (en) * 1997-03-14 1998-09-24 Snow Brand Milk Products Co., Ltd. Agent for preventing and/or treating cachexia
US6130175A (en) * 1997-04-29 2000-10-10 Gore Enterprise Holdings, Inc. Integral multi-layered ion-exchange composite membranes
US6638659B1 (en) 1999-04-30 2003-10-28 University Of Connecticut Membrane electrode assemblies using ionic composite membranes
US8173709B2 (en) * 1999-09-22 2012-05-08 Quadex Pharmaceuticals, Llc Anti-infective methods for treating pathogen-induced disordered tissues
US6759434B2 (en) 1999-09-22 2004-07-06 B. Ron Johnson Anti-infective compositions, methods and systems for treating disordered tissue
US6211243B1 (en) 1999-09-22 2001-04-03 B. Ron Johnson Methods for treating cold sores with anti-infective compositions
US6410597B1 (en) * 2000-02-25 2002-06-25 Virginia Commonwealth University Hydroxyalkyl amide analogs of ceramide
US20050118137A1 (en) * 2000-07-19 2005-06-02 Chih-Ping Liu Method of treatment using interferon-tau
US20050226845A1 (en) * 2004-03-10 2005-10-13 Chih-Ping Liu Method of treatment using interferon-tau
US20050201981A1 (en) * 2004-03-10 2005-09-15 Chih-Ping Liu Method of optimizing treatment with interferon-tau
US7431920B2 (en) * 2000-07-19 2008-10-07 Pepgen Corporation Method of treating IL-10 deficiency
US20050084478A1 (en) * 2000-10-17 2005-04-21 Chih-Ping Liu Combination therapy using interferon-tau
US6613203B1 (en) 2001-09-10 2003-09-02 Gore Enterprise Holdings Ion conducting membrane having high hardness and dimensional stability
US6668753B2 (en) 2002-02-13 2003-12-30 Embrex, Inc. Methods and apparatus for delivering fluid to egg injection devices
US6860225B2 (en) * 2002-05-06 2005-03-01 Embrex, Inc. Methods and apparatus for identifying live eggs by detecting embryo heart rate and/or motion
US7373561B2 (en) * 2002-10-29 2008-05-13 Broadcom Corporation Integrated packet bit error rate tester for 10G SERDES
ES2347239T3 (es) * 2002-12-02 2010-10-27 Amgen Fremont Inc. Anticuerpos dirigidos al factor de necrosis tumoral y usos de los mismos.
US20050100601A1 (en) * 2003-11-07 2005-05-12 Viratox, L.L.C. Virucidal activities of cetylpyridinium chloride
US20090232748A1 (en) * 2003-11-07 2009-09-17 Viratox, L.L.C. Virucidal activities of cetylpyridinium chloride
US20060078942A1 (en) * 2004-03-10 2006-04-13 Pepgen Corporation Method of treatment using interferon-tau
US20080025948A1 (en) * 2004-03-10 2008-01-31 Chih-Ping Liu Methods of Treatment Using Interferon-Tau
US20050244402A1 (en) * 2004-04-30 2005-11-03 Villanueva Julie M Absorption of pain-causing agents
US9023863B2 (en) 2006-07-14 2015-05-05 Stiefel Research Australia Pty Ltd Fatty acid pharmaceutical foam
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
MX2009004134A (es) * 2006-10-20 2009-08-12 Biogen Idec Inc Tratamiento de trastornos de desmielinizacion con el receptor de linfotoxina beta soluble.
US7964588B2 (en) * 2006-11-29 2011-06-21 Redox Phamaceutica Co., Inc. Method for the treatment of psoriasis
WO2008103416A1 (en) * 2007-02-21 2008-08-28 Capps Charles L Synergistic enhancement of calcium propionate
US20120202135A1 (en) 2009-09-03 2012-08-09 E.I. Du Pont De Nemours And Company Improved catalyst coated membranes having composite, thin membranes and thin cathodes for use in direct methanol fuel cells
US9549930B2 (en) 2013-03-14 2017-01-24 Quadex Pharmaceuticals, Llc Combined systemic and topical treatment of disordered and/or prodromal stage tissue
US9463180B2 (en) 2013-03-14 2016-10-11 Quadex Pharmaceuticals, Llc Treatment of molluscum contagiosum
US9125911B2 (en) 2013-03-14 2015-09-08 Quadex Pharmaceuticals, Llc Combined systemic and topical treatment of disordered tissues
WO2018004477A1 (en) 2016-06-28 2018-01-04 Pisak Mehmet Nevzat Surfactants for treatment of skin infections caused by double stranded dna viruses of the herpesviridae or papillomaviridae families

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4020183A (en) * 1974-12-03 1977-04-26 Ortho Pharmaceutical Corporation Nonionic surface active anti-herpes simplex viral agents
US4480032A (en) * 1980-11-13 1984-10-30 Yabrov Alexander A Natural mixture of Type I and Type II interferons
DE3117934A1 (de) * 1981-05-06 1982-12-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Neues peptid, verfahren zu seiner gewinnung und dieses enthaltendes arzneimittel
SE8204382L (sv) * 1981-07-21 1983-01-22 Hayashibara Biochem Lab Sett att framstella malcellysfaktor och anvendning derav
EP0077063B1 (de) * 1981-10-13 1988-03-16 Exovir, Inc. Interferon enthaltende Zusammensetzungen und die Anwendung dieser Zusammensetzungen in der Behandlung von Herpesinfektionen, prämalignen Hautverletzungen, Hautmalignitäten und Psoriasis
US4507281A (en) * 1981-10-13 1985-03-26 Exovir, Inc. Interferon-containing compositions
US4481137A (en) * 1982-02-26 1984-11-06 Mochida Pharmaceutical Co., Ltd. Glycoproteins and processes for their production
US4457916A (en) * 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
ZA844070B (en) * 1983-06-01 1984-12-24 Genentech Inc Gamma interferon-lymphotoxin synergism
JPS6019719A (ja) * 1983-07-15 1985-01-31 Asahi Chem Ind Co Ltd 抗腫瘍活性を有する蛋白質
EP0149551A3 (de) * 1984-01-16 1987-09-23 Genentech, Inc. Synergistische Gamma-Interferon-Interleukin-2-Zusammensetzungen und Verfahren zur Herstellung desselben
DE3423234A1 (de) * 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor
US4650674A (en) * 1984-07-05 1987-03-17 Genentech, Inc. Synergistic cytotoxic composition
EP0256119A4 (de) * 1986-02-10 1988-08-23 Liposome Technology Inc Liposomenverabreichungssystem mit geregelter verabreichung.

Also Published As

Publication number Publication date
US4822605A (en) 1989-04-18
ATE68702T1 (de) 1991-11-15
DK82287A (da) 1987-08-19
EP0233629A1 (de) 1987-08-26
DK82287D0 (da) 1987-02-18
CA1297006C (en) 1992-03-10
AU6879087A (en) 1987-08-20
JPS62240627A (ja) 1987-10-21
ZA87702B (en) 1987-09-30
AU598232B2 (en) 1990-06-21
EP0233629B1 (de) 1991-10-23
DE3773953D1 (de) 1991-11-28

Similar Documents

Publication Publication Date Title
IL82351A (en) Compositions for the treatment of viral and cancerous skin lesions
NZ212632A (en) Tumor necrosis factor, its preparation and its use
MY101852A (en) Tumor necrosis factor, methods for its preparation, containing it, dna encoding it and assay method using such dna.
DE3278234D1 (en) Interferon-containing compositions and the use of these compositions in the treatment of herpetic infections, pre-malignant skin lesions, skin malignancies and psoriasis
DK172276A (da) Pulshastighedsindikator
EP0297733A3 (de) Catecholbutane enthaltende Arzneimittel
ZA854682B (en) Synergistic mixtures of interferons and tumour necrosis factor
AU638982B2 (en) Use of cytokines
IE872344L (en) Compositions suitable for human topical application¹including a growth factor and/or related materials
AU587959B2 (en) The effect of human tumor necrosis factor and human interferon on human cancer cells and methods
IE44431L (en) Pyrimid-2-ones
ES8704547A1 (es) Metodo para producir la proteina factor recombinante de necrosis de tumores hermanos (tnf) a partir de celulas hospedantes competentes transformadas con un vector de expresion.
NZ219027A (en) Antiviral composition containing interferon tumour necrosis factor and/or lymphotoxin
GR3002779T3 (en) Compositions and the use of interleukin-2 and/or interferon-beta and tumour necrosis factor for combination therapy or in providing medicaments or formulations
AU7336687A (en) Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
SU688447A1 (ru) Стекло с анионной проводимостью по брому
Kumagai et al. The Realities of Common Rights in Modern Age
ES8802250A1 (es) Un metodo para producir factor de necrosis de tumores.
Hayashi On the human tracking characteristics of previews control
JPS57144217A (en) Antitumor agent
KATAOKA et al. Antitumor effect of interferon-α, γ and/or tumor necrosis factor-α against human colon cancer line (LoVo) transplanted into nude mice
Carella et al. Value of radiation therapy in the management of patients with cerebral metastases from malignant melanoma: RTOG brain metastases phases I & II
CA816842A (en) Determination of combined carbon in metals